Immix Biopharma Inc expected to post a loss of 23 cents a share - Earnings Preview

Immix Biopharma

25/03/2024 20:03

* Immix Biopharma Inc  IMMX.OQ   IMMX.O  is expected to show
no
change in quarterly revenue when it reports  results on March 27
(estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Immix Biopharma Inc is
for a
loss of 23 cents per share. 
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Immix
Biopharma
Inc is $14.00​, above​ its last closing price of $3.29. ​​​

This summary was machine generated March 25 at 20:03 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)